Table 1 Characteristics of patients in this study
Total number of patients | 33 |
|---|---|
Mean age (Range) | 63.7 (39–83) |
Sex (Male:Female) | 18:15 |
Clinically reported PD-L1 score | |
Based on clone 22C3 | |
TPS < 1% | 10 |
TPS 1–49% | 14 |
TPS ≥ 50% | 6 |
Based on clone SP142 | 1 (TC 0%, IC 15%) |
Based on clone SP263 | |
TPS < 1% | 1 |
TPS 1–49% | 0 |
TPS ≥ 50% | 1 |
Number of patients who Received Immunotherapy | 22 |
Pembrolizumab | 9 |
Nivolumab | 6 |
Atezolizumab | 7 |
Treatment Scenario | |
Stage IV Disease | 19 |
Adjuvant | 2 |
Neoadjuvant | 1 |